Loading
A family of 'time to X' endpoints: how long until the cancer grows (TTP, which unlike PFS ignores deaths), until the patient needs another treatment (TTNT), until it spreads (metastasis-free survival), or until symptoms worsen. Each captures something patients care about that survival alone misses.
Time to progression counts only progression events, censoring deaths, so it is used where competing mortality is high but is less favoured than PFS by regulators. Time to next treatment and PFS2 (progression on the next line) reflect whether a benefit persists beyond the trial drug and whether early use compromises later options. Metastasis-free survival is a validated surrogate for overall survival in localised prostate cancer and the endpoint of several approvals in non-metastatic castration-resistant disease; radiographic PFS is standard in prostate trials because PSA changes alone are unreliable. Time to deterioration of quality of life is a patient-reported time-to-event endpoint increasingly demanded by regulators and HTA bodies.
Shares Event-free / disease-free survival (EFS, DFS, iDFS, RFS), Progression-free survival (PFS), Overall survival (OS).
Shares Progression-free survival (PFS), Overall survival (OS).
Shares Progression-free survival (PFS), Overall survival (OS).
Shares Progression-free survival (PFS), Overall survival (OS).
Shares Progression-free survival (PFS), Overall survival (OS).
Shares Progression-free survival (PFS), Overall survival (OS).
Shares Progression-free survival (PFS), Overall survival (OS).
Shares Progression-free survival (PFS), Overall survival (OS).